Deverra Therapeutics

Deverra Therapeutics is a biotechnology startup founded in 2019 with a primary focus on developing allogeneic, off-the-shelf cellular immunotherapies for on-demand treatment of patients with cancer and infectious diseases. The company holds an exclusive license to a proprietary stem cell expansion and directed-differentiation platform from the Fred Hutchinson Cancer Research Center, which is backed by over 20 years of federally funded research and data from 5 clinical trials. This cutting-edge platform enables the generation of a variety of unmodified and modified immune cells tailored for the treatment of cancer and infectious diseases. Deverra Therapeutics recently secured a $3.50 million grant investment from the Andy Hill Cancer Research Endowment (CARE) Fund on 11 September 2023. This funding injection is expected to bolster the company's research and development efforts in advancing its cell therapy technologies. With its innovative approach and strong backing from reputable institutions, Deverra Therapeutics is positioning itself as a key player in the biotechnology space, offering promising prospects for the future of cellular immunotherapies.